15/10/02说明:此前论坛服务器频繁出错,现已更换服务器。今后论坛继续数据库备份,不备份上传附件。

肝胆相照论坛

 

 

肝胆相照论坛 论坛 学术讨论& HBV English Liver grafts from anti-hepatitis B core positive don ...
查看: 1122|回复: 0
go

Liver grafts from anti-hepatitis B core positive donors: A systematic review. [复制链接]

Rank: 8Rank: 8

现金
62111 元 
精华
26 
帖子
30437 
注册时间
2009-10-5 
最后登录
2022-12-28 

才高八斗

1
发表于 2010-1-2 21:48 |只看该作者 |倒序浏览 |打印
J Hepatol. 2009 Dec 22. [Epub ahead of print]

Liver grafts from anti-hepatitis B core positive donors: A systematic review.

Cholongitas E, Papatheodoridis GV, Burroughs AK.

The Royal Free Sheila Sherlock Liver Centre and University, Department of
Surgery, Royal Free Hospital, Pond Street, Hampstead, London NW3 2QG, UK.


BACKGROUND & AIMS: Although hepatitis B virus (HBV) transmission after liver
transplantation of grafts from HBsAg-negative, anti-HBc positive donors is
well established, the growing organ shortage favours the use of such marginal
grafts. We systematically evaluated the risk of HBV infection after liver
transplantation with such grafts and the effect of anti-HBV prophylaxis.
METHODS: We performed a literature review over the last 15years identifying 39
studies including 903 recipients of anti-HBc positive liver grafts. RESULTS:
Recurrent HBV infection developed in 11% of HBsAg-positive liver transplant
recipients of anti-HBc positive grafts, while survival was similar (67-100%)
to HBsAg-positive recipients of anti-HBc negative grafts. De novo HBV
infection developed in 19% of HBsAg-negative recipients being less frequent in
anti-HBc/anti-HBs positive than HBV naive cases without prophylaxis (15% vs
48%, p<0.001). Anti-HBV prophylaxis reduced de novo infection rates in both
anti-HBc/anti-HBs positive (3%) and HBV naive recipients (12%). De novo
infection rates were 19%, 2.6% and 2.8% in HBsAg-negative recipients under
hepatitis B immunoglobulin, lamivudine and their combination, respectively.
CONCLUSIONS: Liver grafts from anti-HBc positive donors can be safely used,
preferentially in HBsAg-positive or anti-HBc/anti-HBs positive recipients.
HBsAg-negative recipients should receive prophylaxis with lamivudine, while
both anti-HBc and anti-HBs positive recipients may need no prophylaxis at all.
Copyright © 2009 European Association for the Study of the Liver. Published
by Elsevier B.V. All rights reserved.
‹ 上一主题|下一主题
你需要登录后才可以回帖 登录 | 注册

肝胆相照论坛

GMT+8, 2024-11-1 11:37 , Processed in 0.012444 second(s), 11 queries , Gzip On.

Powered by Discuz! X1.5

© 2001-2010 Comsenz Inc.